Excelimmune Nabs $10.5M Series B Deal

Xconomy Boston — 

Excelimmune, a Woburn, MA-based developer of a human recombinant polyclonal antibody-based drugs, announced today that it had wrapped up a $10.5 million Series B financing, from new and previous high net worth individual backers. The money will go to enhancing Excelimmune’s discovery platform and manufacturing processes, and toward development of Staphguard, the company’s treatment for Staph infections resistant to methicillin. Last July Excelimmune brought in $4.5 million in equity financing from two investors.